



Journal of Oncology Research and Treatments

Relationship between Vitamin D Deficiency and Bppv

BPPV occurrence

VIT D deficiency can change the structure of the otoconia, which are made of calcium carbonate. Such structural changes may induce otoconia to easily detach from the otolith organ, leading to BPPV attacks. A prospective study in Egypt suggested that low VIT D levels were related to BPPV development; the mean VIT D level in the BPPV group (16.04 ng/ml) was significantly lower than the healthy control (19.53 ng/ml) [3]. Another prospective study demonstrated a significantly lower VIT D level in BPPV patients, including those who experienced their first episodes and recurrent vertigo patients. This observation suggested that VIT D deficiency might be a risk factor for BPPV [10]. In a Korean study where postmenopausal BPPV female patients were classified into three groups (normal, osteopenia and osteoporosis) according to the Bone Mineral Density (BMD), multiple logistic regression analyses showed that VIT D deficiency was positively related to osteoporosis in BPPV. VIT D deficiency and osteoporosis were found to be risk factors for BPPV [11]. In a retrospective study that included 380 BPPV patients and 3125 control subjects, divided into age- and gender-based subgroups, differences in the serum VIT D existed among different age groups and genders. Lower VIT D level was a risk factor in both male and female patients aged less than 40 and females aged 40-69 and 60-69 years. Interestingly, a recent study reported that the mean age years of male BPPV subjects and healthy controls were 62.1 ± 10.6 and 59.4 ± 13.2 , with no statistically significant difference in age between the two groups. The mean VIT D level was 20.99 ± 6.76 ng/ml and 23.17 ± 6.49 ng/ml in the BPPV patients and controls, and 25(OH)D was identified as a risk factor of BPPV in males [12].

Otolin-1 is an inner ear protein exclusively expressed in otoconia and cells of the vestibule and cochlea. Interestingly, a prospective study found high otolin-1 levels in BPPV patients, suggesting that it may be a potential serum marker for BPPV patients. However, no statistical significance in low VIT D levels was found between BPPV patients and controls [4]. Two limitations of that study included the small sample size and the high percentage of post-traumatic BPPV patients (13%).

BPPV recurrence

In the previously mentioned Egyptian prospective study, the BPPV patients were divided into a non-recurrent and recurrent group according to BPPV recurrence at one-year follow-up. VIT D levels in the non-recurrent group (16.04 ng/ml) were significantly higher than in the recurrent group (11.93 ng/ml) ($P=0.046$), which suggested that recurrent attacks of BPPV were associated with lower VIT D levels [3]. Similarly, in another prospective cohort study, a statistically significantly greater proportion of VIT D deficiency (serum 25(OH)D < 20 ng/ml) patients was found in the recurrent BPPV group, compared to the non-recurrent BPPV group (68% vs 37%), with significantly higher mean VIT D levels in the latter group (19.53 ± 15.33 vs 25.85 ± 14.10 ng/ml) [13]. Wang et al. reported lower serum 25-(OH)VIT D levels in middle-aged and elderly women with recurrent BPPV (17.15 ± 2.028 ng/ml) compared to an age-matched healthy control group (23.84 ± 3.125 ng/ml) [14]. During the comparison between non-postmenopausal and postmenopausal women within the recurrent BPPV group, decreased serum VIT D levels (16.231 ± 2.102 ng/ml) were found in women over 50, especially postmenopausal ones. In a study by Gu Il Rhim, during a 2-year follow-up period, BPPV recurrence rates were significantly different at different VIT D levels, while two cut-off points for 25-(OH) VIT D were 10 ng/ml and 15 ng/ml. Setting the cut-off point was 15

ng/ml, greater and less than 15 ng/ml the recurrence rates respectively were 60% and 40%, the recurrence was increasing with the declining of serum VIT D level, it indicated that the low serum VIT D levels significantly affected the recurrence of BPPV [15].

On the contrary, no significant difference in 25-(OH) VIT D level was found in patients first diagnosed with BPPV (21.0 ± 5.9 ng/ml) and recurrent BPPV patients (21.9 ± 4.9 ng/ml) in a prospective study [10]. A meta-analysis that assessed the risk factors for BPPV recurrence concluded that VIT D did not contribute to BPPV recurrence [16].

to BPPV attacks. Most clinical trials found that VIT D deficiency was a risk factor for BPPV occurrence. Although the association between VIT D deficiency and recurrence for BPPV was indefinite, many studies indicated that VIT D supplements were beneficial to BPPV patients with VIT D deficiency. VIT D supplementation not only reduced BPPV recurrence but also helped prevent injury caused by VIT D deficiency to other body organs. Accordingly, we recommend quantifying serum VIT D levels in BPPV patients and dietary or drug supplementation for hypovitaminosis D. Although most trials supported the VIT D supplementation, high-quality clinical trials were sparse. Currently, there is no consensus on VIT D supplementation for VIT D deficiency.

Acknowledgment

We received a grant from the research that the relevance and clinical significance between NO concentration of nose expiratory and allergic rhinitis.

Conflict of Interest

The authors declare no conflicts of interest.

References

1. Brevern MV, Radtke A, Lezius F, Feldmann M, Ziese T, et al. (2006) Epidemiology of benign paroxysmal positional vertigo: A Population based study. *J Neurol Neurosurg Psychiatry* 78: 710-715.
2. Zhu CT, Zhao XQ, Ju Y, Wang Y, Chen MM, et al. (2019) Clinical characteristics and risk factors for the recurrence of benign paroxysmal positional vertigo. *Frontiers in Neurology* 10: 1190.
3. Talaat HS, Abuhadied G, Talaat AS, Abdelaal MSS (2015) Low bone mineral density and vitamin D deficiency in patients with benign positional paroxysmal vertigo. *Eur Arch Oto Rhino L* 272: 2249-2253.
4. Yadav H, Irugu DVK, Krishanan LR, Singh A, Abraham R, et al. (2021) An Evaluation of serum otolecin-1 and vitamin-D in benign paroxysmal positional vertigo. *Res Vestib Sci* 2021: 1-8.
5. Walther LE, Blödw S, Buder J, Kniep (2014) Principles of calcite dissolution in